Wir sind mit live! Mehr erfahren

Immix Biopharma

IMMX

Börsenwert 662 Mio. $

7,98 USD

-0,70

8,06 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

7,99

+0,01

0,13 %

1 Tag

-8,06 %

5 Tage

-15,29 %

1 Monat

-33,05 %

3 Monate

-20,68 %

6 Monate

-19,88 %

Seit Jahresbeginn

46,96 %

1 Jahr

195,56 %

5 Jahre

117,44 %

10 Jahre

117,44 %

Profil: Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Mitarbeiter: 21

Gesundheitswesen Biotechnologie

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 5,6 %

Neutral 94,4 %

Negativ 0 %

Neutral

GlobeNewsWire

vor 11 Tagen

Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference

LOS ANGELES, CA, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in AL Amyloidosis, today announced that it will present at the 45th Annual J.P. Morgan Healthcare Conference being held January 11-14, 2027 in San Francisco, CA.

Positiv

MarketBeat

vor 12 Tagen

Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study

Immix Biopharma NASDAQ: IMMX reported updated clinical data for NXC-201, its investigational CAR T-cell therapy for relapsed or refractory light-chain (AL) amyloidosis, and outlined plans for a biologics license application, a frontline study and a targeted commercial launch strategy.

Neutral

GlobeNewsWire

vor 16 Tagen

Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock

LOS ANGELES, CA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of 11,363,637 shares of its common stock at a public offering price of $11.00 per share.

Neutral

Seeking Alpha

vor 17 Tagen

Immix Biopharma, Inc. (IMMX) Shareholder/Analyst Call Transcript

Neutral

GlobeNewsWire

vor 17 Tagen

Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock

LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an underwritten registered offering of 11,363,637 shares of its common stock at a public offering price of $11.00 per share. The gross proceeds from this offering are expected to be $125 million, before deducting underwriting discounts and commissions and offering expenses payable by the Company. The offering is expected to close on or about September 30, 2026, subject to the satisfaction of customary closing conditions.

Neutral

GlobeNewsWire

vor 17 Tagen

Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis

– 100% (25/25) of new patients are either in complete response (CR) or MRD-negative (21/25 are in CR; remaining 4/25 are MRD-negative) –

$Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis$